China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D
This article was originally published in PharmAsia News
Executive Summary
Shanghai Institute of Materia Medica (SIMM) and French pharmaceutical company Servier Laboratories signed an agreement on the R&D of targeted antitumor drug candidate lucitanib.
You may also be interested in...
Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
Minute Insight: Inbound Health Now Offers Post-Surgical Hospital Care At Patients’ Homes
The hospital-to-home care movement is rising, and Inbound Health wants to be at the forefront of enabling health systems and health plans nationwide to bring hospital-level care into the home, now adding general surgery to its offerings.